Mazdutide
Dual GLP-1/Glucagon Receptor Agonist (IBI362)
Mechanism of Action
Dual GLP-1 and glucagon receptor agonist. GLP-1 agonism suppresses appetite and slows gastric emptying; glucagon receptor agonism increases energy expenditure and lipid oxidation, aiming to offset the metabolic-rate decline seen with GLP-1 monotherapy.
Key Benefits
- Significant weight loss in Chinese phase 3 trials (DREAMS program)
- Improved glycemic control, outperforming dulaglutide on both weight and HbA1c
- Improved waist circumference, lipids, liver enzymes, and uric acid
- Glucagon co-agonism may offset the metabolic-rate decline seen with GLP-1 monotherapy
Dosing Protocol
Almost all efficacy/safety data is from Chinese trials (DREAMS program); multi-ethnic long-term data still pending. Titrate similarly to other GLP-1-class agents.
Ideal Candidates
Adults with obesity and/or T2D, particularly those seeking a dual-mechanism option; data is predominantly in Chinese populations.
Side Effects & Safety
Gastrointestinal effects (nausea, diarrhea) more frequent than comparators; serious adverse event and discontinuation rates comparable to dulaglutide/semaglutide.
Regulatory Status
Gray AreaApproved in China (NMPA, 2025) for weight/glycemic management; not FDA-approved in the US. No 503A listing — research/international sourcing only.
Evidence & Citations
Frequently asked
What is Mazdutide?+
Mazdutide (Dual GLP-1/Glucagon Receptor Agonist (IBI362)) is a peptide studied for dual receptor agonist and weight loss. Dual GLP-1 and glucagon receptor agonist. GLP-1 agonism suppresses appetite and slows gastric emptying; glucagon receptor agonism increases energy expenditure and lipid oxidation, aiming to offset the metabolic-rate decline seen with GLP-1 monotherapy.
What is the dosing protocol for Mazdutide?+
Literature commonly references 3 mg/wk (low) to 6 mg/wk (maintenance) via SubQ weekly, on a ongoing cycle. Educational reference only — a licensed Stackhaus Health provider sets any personalized protocol.
What is the regulatory status of Mazdutide?+
Approved in China (NMPA, 2025) for weight/glycemic management; not FDA-approved in the US. No 503A listing — research/international sourcing only.
Where can I access Mazdutide?+
Research-grade Mazdutide is available through Stackhaus Research. For a personalized, provider-reviewed protocol, consult a licensed clinician through Stackhaus Health.